Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

[The relevant factors and strategies related efficacy with standard of care in chronic hepatitis C treatment naive patients].

Dou XG.

Zhonghua Gan Zang Bing Za Zhi. 2013 Jun;21(6):406-7. Chinese. No abstract available.

PMID:
24490300
2.

Ribavirin in chronic hepatitis C: past and future.

Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):249-53. doi: 10.1586/eri.09.5. No abstract available.

PMID:
19344238
3.

Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.

Figlerowicz M, Sluzewski W, Kowala-Piaskowska A, Mozer-Lisewska I.

Eur J Pediatr. 2004 Apr;163(4-5):265-7. Epub 2004 Feb 27. No abstract available.

PMID:
14991399
4.

Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects.

Abdo AA, Sanai FM.

Ann Saudi Med. 2009 Jan-Feb;29(1):1-3. No abstract available.

5.

[Effect of interferon and ribavirin combination therapy in sixty-two patients with chronic hepatitis C originating from a single blood donor].

Liu SD, Cheng ML, Ren H, Yang QK, Shu DY.

Zhonghua Gan Zang Bing Za Zhi. 2012 Aug;20(8):589-92. doi: 10.3760/cma.j.issn.1007-3418.2012.08.010. Chinese.

PMID:
23207152
6.

A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.

Tassopoulos NC, Ketikoglou I, Tsantoulas D, Raptopoulou M, Hatzis G, Vafiadis I, Sidiropoulos L, Kanatakis S, Anagnostopoulos G, Sypsa V, Hatzakis A; Hellenic Viral Hepatitis Research Network.

J Viral Hepat. 2003 Sep;10(5):383-9.

PMID:
12969190
7.

A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.

Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.

Eur J Gastroenterol Hepatol. 2013 May;25(5):601-5. doi: 10.1097/MEG.0b013e32835cc899.

PMID:
23263720
8.

Peginterferon plus ribavirin over two years may be successful in patients with chronic hepatitis C and a very slow virologic response.

Ordubadi P, Gschwantler M.

Scand J Gastroenterol. 2009;44(9):1150-1. doi: 10.1080/00365520903104434. No abstract available.

PMID:
19593689
9.

Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.

Urbanek P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Husa P.

Eur J Gastroenterol Hepatol. 2011 Nov;23(11):1004-10. doi: 10.1097/MEG.0b013e32834b326b.

PMID:
21904204
10.

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.

Powis J, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C, Krajden M, Deschenes M, Balshaw RF, Heathcote EJ, Yoshida EM; Canadian Pegasys Study Group.

J Viral Hepat. 2008 Jan;15(1):52-7.

11.
12.

[Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment].

Zoulim F.

Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B225-30. Review. French. No abstract available.

PMID:
12180293
13.

[Treatment of patients with chronic hepatitis C who have not been previously treated].

Marcellin P, Boyer N.

Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B194-201. Review. French. No abstract available.

PMID:
12180288
14.

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.

Cavalletto L, Chemello L, Donada C, Casarin P, Belussi F, Bernardinello E, Marino F, Pontisso P, Gatta A, Alberti A.

J Hepatol. 2000 Jul;33(1):128-34.

PMID:
10905596
15.

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.

Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, Borghesio E, Rizzetto M, Saracco G.

Hepatology. 1998 Aug;28(2):341-6.

PMID:
9695995
16.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
17.

Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.

[No authors listed]

Ann Intern Med. 2013 Dec 3;159(11):I-14. doi: 10.7326/0003-4819-159-11-201312030-00001. No abstract available.

PMID:
24297207
18.

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.

Tinè F, Graviano D, Giannuoli G, Madonia S, Malizia G, Patti S, Fasola S, Cottone M, D'Amico G; at Liver Study Group of Villa Sofia-Cervello Hospital (LSVSCH).

Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1113-23. doi: 10.1002/pds.2025.

PMID:
20848397
19.

Infectious disease. Despite setbacks, optimism on drugs for hepatitis C.

Cohen J.

Science. 2012 Sep 21;337(6101):1450-1. No abstract available.

PMID:
22997303
20.

Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M.

Mol Ther. 2013 Sep;21(9):1796-805. doi: 10.1038/mt.2013.119. Epub 2013 Jun 11.

Items per page

Supplemental Content

Write to the Help Desk